Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Licensing Agreements 21
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
Equity Offering 32
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
Acquisition 37
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG – Key Competitors 39
MorphoSys AG – Key Employees 40
MorphoSys AG – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 02, 2018: MorphoSys reports second quarter 2018 financial results 42
May 02, 2018: MorphoSy Reports First Quarter 2018 Results 44
Mar 13, 2018: MorphoSys Presents Results for Fiscal Year 2017 46
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 49
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 51
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 53
Corporate Communications 55
Jul 24, 2018: MorphoSys Appoints Jennifer Herron as President of MorphoSys US and Executive Vice President, Global Commercial 55
May 17, 2018: Annual General Meeting of MorphoSys Elects New Supervisory Board Members 56
Apr 10, 2018: MorphoSys Nominates New Candidates for Supervisory Board 57
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSys’s Chief Scientific Officer 58
Product News 59
06/15/2018: MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 59
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 60
05/17/2018: MorphoSys Announces Presentation of Clinical Data on CD38 antibody MOR202 at Upcoming EHA 2018 Conference 61
Product Approvals 62
Aug 08, 2018: MorphoSys and I-Mab Biopharma announce China IND submission of TJ202/MOR202 62
Clinical Trials 63
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 63
Feb 21, 2017: MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 64
Other Significant Developments 65
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 65
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG, Key Competitors 39
MorphoSys AG, Key Employees 40
MorphoSys AG, Subsidiaries 41
List of Figures
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10